Profusa Celebrates Significant Business Milestone
Profusa, Inc. has achieved a remarkable milestone in its journey, marking its transition to a public entity with trading expected on Nasdaq under the ticker symbol "PFSA." This step follows its business combination with NorthView Acquisition Corp., a strategic move aiming to accelerate growth in the dynamic digital health landscape.
A Vision for Personalized Health Monitoring
The company, which has its home base in Berkeley, California, is committed to revolutionizing how individuals monitor their health through innovative technology. The platform developed by Profusa is designed for the continuous monitoring of biochemical signals within the body, offering a pathway to enhanced chronic disease management, including conditions like diabetes and peripheral arterial disease (PAD).
Empowering Patients with Real-Time Data
Profusa's advanced biosensor technology holds the potential to deliver timely and actionable data directly to users and healthcare providers alike. This development signifies an evolution in patient care, where actionable insights can facilitate more informed health decisions.
Financial Strategies to Support Growth
To assist in the transition into public trading and establish a solid financial footing, Profusa successfully raised $9 million through a secured convertible promissory note. This funding is not only crucial for covering transaction costs but will also bolster ongoing operational needs.
Advisory Collaborations Enhance Market Entry
The road to this public listing has been paved through strategic partnerships with renowned advisors including A.G.P./Alliance Global Partners, I-Bankers Securities, and Dawson James Securities, all of whom provided financial guidance throughout the acquisition process.
About Profusa and Its Innovative Approach
Profusa is at the forefront of commercial digital health innovations, focusing on developing long-lasting, injectable biosensors aimed at personal and medical applications. The company strives to furnish healthcare professionals and patients with reliable, biometric data analytics that empower them to take charge of their health journeys and respond proactively to their conditions.
Long-Term Commitment to Healthcare Innovation
Profusa's leadership, including its accomplished CEO, Ben Hwang, Ph.D., is driven by the mission to utilize cutting-edge scientific advancements to significantly improve health outcomes. The focus remains on creating a sustainable health technology that is both affordable and user-friendly.
Frequently Asked Questions
What is Profusa's core business focus?
Profusa specializes in developing digital health technologies, particularly innovative biosensors for continuous health monitoring.
When does Profusa start trading on Nasdaq?
Profusa is set to begin trading on Nasdaq under the ticker symbol "PFSA" on the designated trading day determined by the exchange following the acquisition.
What are the expected benefits of Profusa's technology?
Profusa’s technology aims to empower users by providing real-time health data that enhances personal health monitoring and management of chronic diseases.
How much funding did Profusa raise during the business combination?
Profusa raised $9 million through a secured convertible promissory note to support transaction costs and future operational requirements.
Who advised Profusa during its merger with NorthView Acquisition Corp?
Profusa was advised by A.G.P./Alliance Global Partners, I-Bankers Securities, and Dawson James Securities regarding its merger strategy and financial planning.
